Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma.
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ pharmacology
Dose-Response Relationship, Drug
Female
Fluorodeoxyglucose F18
Humans
Male
Mesothelioma, Malignant
/ diagnostic imaging
Middle Aged
Natriuretic Peptide, Brain
Peptide Fragments
Positron Emission Tomography Computed Tomography
Retrospective Studies
Treatment Outcome
PET/CT
checkpoint inhibitor
mesothelioma
pembrolizumab
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
24
03
2020
accepted:
19
05
2020
pubmed:
14
6
2020
medline:
30
4
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
Fixed-dose pembrolizumab (200 mg absolute, day 1, every 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the phase 3 PROMISE-meso trial compared with second-line chemotherapy. Because of lack of validated imaging response criteria, responder subgroups with potential survival benefit have not yet been identified. Here, we administered high-dose pembrolizumab (10 mg/kg, day 1, every 2 wk) considering the KEYNOTE-028 trial and assessed the prognostic value of PET metabolic response in patients with chemotherapy-resistant malignant mesothelioma of the pleura or peritoneum.
Identifiants
pubmed: 32532926
pii: jnumed.120.245803
doi: 10.2967/jnumed.120.245803
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Natriuretic Peptide, Brain
114471-18-0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-194Informations de copyright
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.